Clinical Trial to Evaluate the Efficacy and Safety of DWKH
NCT ID: NCT05683951
Last Updated: 2023-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
186 participants
INTERVENTIONAL
2021-11-26
2022-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212
NCT07093697
Point of Care Polymerase Chain Reaction (PCR) Diagnostics of Respiratory Tract Infections in General Practice
NCT06120153
A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis
NCT05344638
Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies
NCT01363531
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
NCT04500132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DWKH
DWKH
Administration of DWKH three times daily
DWKH-R
DWKH-R
Administration of DWKH-R three times daily
PLACEBO
Placebo
Administration of Placebo three times daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DWKH
Administration of DWKH three times daily
DWKH-R
Administration of DWKH-R three times daily
Placebo
Administration of Placebo three times daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients whose BSS score is over 5.
Exclusion Criteria
* Moderate liver disease (ALT or AST \> UNLx3).
* Moderate lung disease.
* Uncontrolled HTN.
* Uncontrolled DM.
* Uncontrolled thyroidism.
* Patients who is needed antibiotics during the study period.
* In the case of women, pregnant(Urine-HCG positive) or lactating women.
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewon Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DWKH-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.